GDS’s June insights covers Buffett’s legacy, Novo’s rebound, and Rivian’s rise. Click here to read the full note now.

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothol ...

Similarly, experts suggest that type two diabetes drug Ozempic, could actually be increasing penis sizes via illusion.

The analyst is thus maintaining a cautious stance on the stock. Novo Nordisk A/S (NYSE:NVO) is a global healthcare company ...